Summary for Clinicians: 2019 Clinical Practice Guideline Summary for the Treatment of Drug-Resistant Tuberculosis
- 1 August 2020
- journal article
- editorial
- Published by American Thoracic Society in Annals of the American Thoracic Society
- Vol. 17 (8), 911-917
- https://doi.org/10.1513/annalsats.202004-318cme
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based RecommendationsAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimineEuropean Respiratory Journal, 2016
- Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimineEuropean Respiratory Journal, 2016
- Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data MetaanalysisClinical Infectious Diseases, 2016
- Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and BedaquilineAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Safety and Tolerability Profile of Second-Line Anti-Tuberculosis MedicationsDrug Safety, 2015
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLoS Medicine, 2012
- Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysisEuropean Respiratory Journal, 2012
- Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence settingThe International Journal of Tuberculosis and Lung Disease, 2012
- WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 updateEuropean Respiratory Journal, 2011